Ahmad Abdulhadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmad Abdulhadi has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Abdullahi Zainab Zubairu
College of medical sciences, Ahmadu Bello University, Zaria, Nigeria
1 shared publication - Adolphe Karegeya
College of Nursing, University of Utah, Utah, USA
1 shared publication - Amidu Alhassan
Department of Adult Health, School of Nursing and Midwifery, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana
1 shared publication - Aminu Shehu
Department of Microbiology, Faculty of Life Sciences, Bayero University, Kano, Nigeria
1 shared publication - Araj Naveed Siddiqui
Department of Internal Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication - Aymar Akilimali
Faculty of Medicine University of Goma Goma DR Congo
1 shared publication
Latest Publications
- Open Access
- 18 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 443-450
Multidrug-resistant tuberculosis (MDR-TB): an evolving threat to the Nigerian health system – a review
Multidrug-resistant tuberculosis (MDR-TB) is an increasing public health issue that threatens the efforts in the treatment and control of tuberculosis (TB) worldwide, including in Nigeria. According to the World Health Organization, there were 558 000 MDR-TB cases globally in 2019. Nigeria, being the most populous country in Africa, is said to carry a larger proportion of MDR-TB in the world. If not addressed promptly, many Nigerian populations will continue to suffer from MDR-TB, which could result in increased morbidity and mortality rates. Eliminating the threat of MDR-TB in Nigeria requires a multifaceted approach that combines national and international efforts. These approaches should be centered on the molecular testing of MDR-TB using line probe assays and GeneXpert MTB/RIF technology, which enables early and efficient diagnosis of Mycobacterium tuberculosis and TB drug resistance among patients in high-risk populations. Improvements can occur through the development and implementation of new treatment therapies and investment in research to discover additional treatment options for TB. Public awareness and education about the disease are also important. If these recommendations are implemented, they can significantly decrease the burden of MDR-TB in Nigeria.
- 18 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 443-450
Open AccessMultidrug-resistant tuberculosis (MDR-TB): an evolving threat to the Nigerian health system – a review
Multidrug-resistant tuberculosis (MDR-TB) is an increasing public health issue that threatens the efforts in the treatment and control of tuberculosis (TB) worldwide, including in Nigeria. According to the World Health Organization, there were 558 000 MDR-TB cases globally in 2019. Nigeria, being the most populous country in Africa, is said to carry a larger proportion of MDR-TB in the world. If not addressed promptly, many Nigerian populations will continue to suffer from MDR-TB, which could result in increased morbidity and mortality rates. Eliminating the threat of MDR-TB in Nigeria requires a multifaceted approach that combines national and international efforts. These approaches should be centered on the molecular testing of MDR-TB using line probe assays and GeneXpert MTB/RIF technology, which enables early and efficient diagnosis of Mycobacterium tuberculosis and TB drug resistance among patients in high-risk populations. Improvements can occur through the development and implementation of new treatment therapies and investment in research to discover additional treatment options for TB. Public awareness and education about the disease are also important. If these recommendations are implemented, they can significantly decrease the burden of MDR-TB in Nigeria.